Skip to main content
SpringerLink
Log in

Does Irbesartan Improve the Risk of Death or Hospitalization for Cardiovascular Causes Among Patients With HF and PEF?

  • Clinical Trial Report
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.

    Article  CAS  PubMed  Google Scholar 

  2. Cleland JG, Tendera M, Adamus J, et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338–2345.

    Article  CAS  PubMed  Google Scholar 

  3. Benedict CR, Weiner DH, Johnstone DE, et al.: Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993, 22(4 Suppl A):146A–153A.

    Article  CAS  PubMed  Google Scholar 

  4. Kitzman DW, Little WC, Brubaker PH, et al.: Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144–2150.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. JoAnn Lindenfeld has been a consultant for Medtronic, Merck, Boston Scientific, and Forest. She has also received grants from Merck and Sonologic.

Author information

Authors and Affiliations

  1. Cardiac Transplant Program, University of Colorado Health Sciences Center, 1635 Aurora Court, F749, Room 7083, Aurora, CO, 80045, USA

    JoAnn Lindenfeld

Authors
  1. JoAnn Lindenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to JoAnn Lindenfeld.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindenfeld, J. Does Irbesartan Improve the Risk of Death or Hospitalization for Cardiovascular Causes Among Patients With HF and PEF?. Curr Cardiol Rep 12, 193–195 (2010). https://doi.org/10.1007/s11886-010-0099-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-010-0099-4

Keywords

Search

Navigation